Obesity Research & Clinical Practice
Volume 4, Issue 4 , Pages e271-e276 , October 2010

Effect of obesity on TAFI in postmenopausal period

  • Bengur Taskiran

      Affiliations

    • Diyarbakir State Hospital, Diyarbakir, Turkey
    • Corresponding Author InformationCorresponding author. Tel.: +90 532 701 56 05.
    • ,
  • Sibel Guldiken

      Affiliations

    • Trakya University, Department of Endocrinology, Turkey
    • ,
  • Ahmet M. Demir

      Affiliations

    • Trakya University, Department of Haematology, Turkey
    • ,
  • Tulay K. Okman

      Affiliations

    • Trakya University, Department of Gynecology and Obstetrics, Turkey
    • ,
  • Ender Arikan

      Affiliations

    • Acibadem Hospital, Department of Endocrinology, Turkey
    • ,
  • Burhan Turgut

      Affiliations

    • Trakya University, Department of Haematology, Turkey
    • ,
  • Ayse A. Tugrul

      Affiliations

    • Trakya University, Department of Endocrinology, Turkey

Received 28 December 2009 ,Revised 18 May 2010 ,Accepted 27 May 2010.

References 

  1. Abbasi F, Brown BW, Lamendola C, McLaughlin T, Reaven GM. Relationship between obesity, insulin resistance, and coronary heart disease risk. J Am Coll Cardiol. 2002;40:937–943
  2. Jousilahti P, Tuomilehto J, Vartiainen E, Pekkanen J, Puska P. Body weight, cardiovascular risk factors, and coronary mortality. 15-year follow-up of middle-aged men and women in eastern Finland. Circulation. 1996;93:1372–1379
  3. Poehlman ET, Tchernf A. Traversing the menopause: changes in energy expenditure and body composition”. Coron Artery Dis. 1998;9:799–803
  4. Tchernof A, Poehlman ET, Despres JP. Body fat distribution, the menopause transition, and hormone replacement therapy. Diabetes Metab. 2000;26:12–20
  5. Vague P, Juhan-Vague I, Chabert V, Alessi MC, Atlan C. Fat distribution and plasminogen activator inhibitor activity in nondiabetic obese women. Metabolism. 1989;38:913–915
  6. Kitagawa N, Yano Y, Gabazza EC, Bruno NE, Araki R, Matsumoto K, et al. Different metabolic correlations of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 in non-obese type 2 diabetic patients. Diabetes Res Clin Pract. 2006;73(2):150–157
  7. Lind L. Circulating markers of inflammation and atherosclerosis. Atherosclerosis. 2003;169:203–214
  8. Hamsten A, de Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet. 1987;2:3–9
  9. Juhan-Vague I, Alessi MC, Vague P. Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis. Diabetologia. 1991;34:457–462
  10. Wiman B, Hamsten A. The fibrinolytic enzyme system and its role in the etiology of thromboembolic disease. Semin Thromb Hemost. 1990;16:207–216
  11. Bajzar L, Nesheim ME, Tracy PB. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent. Blood. 1996;88(6):2093–2100
  12. Mosnier LO, von dem Borne PA, Meijers JC, Bouma BN. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation. Thromb Haemost. 1998;80(5):829–835
  13. Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem. 1995;270:14477–14484
  14. Hendriks D, Scharpe S, van Sande M, Lommaert MP. Characterisation of a carboxypeptidase in human serum distinct from carboxypeptidase N. J Clin Chem Clin Biochem. 1989;27:277–285
  15. Bouma BN, Meijers JC. Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U). J Thromb Haemost. 2003;1:1566–1574
  16. Eaton DL, Malloy BE, Tsai SP, Henzel W, Drayna D. Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase B from human plasma. J Biol Chem. 1991;266:21833–21834
  17. Boffa MB, Wang W, Bajzar L, Nesheim ME. Plasma and recombinant thrombin-activable fibrinolysis inhibitor (TAFI) and activated TAFI compared with respect to glycosylation, thrombin/thrombomodulin-dependent activation, thermal stability, and enzymatic properties. J Biol Chem. 1998;273:2127–2135
  18. Redlitz A, Tan AK, Eaton DL, Plow EF. Plasma carboxypeptidase as regulators of the plasminogen system. J Clin Invest. 1995;96:2534–2538
  19. Wang W, Boffa MB, Bajzar L, Walker JB, Nesheim ME. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor. J Biol Chem. 1998;273:27176–27181
  20. Sato T, Miwa T, Akatsu H, Matsukawa N, Obata K, Okada N, et al. Pro-carboxypeptidase R is an acute phase protein in the mouse, whereas carboxypeptidase N is not. J Immunol. 2000;165:1053–1058
  21. Campbell W, Okada N, Okada H. Carboxypeptidase R is an inactivator of complement-derived inflammatory peptides and an inhibitor of fibrinolysis. Immunol Rev. 2001;180:162–167
  22. Hendriks D, Wang W, van Sande M, Scharpé S. Human serum carboxypeptidase U: a new kininase?. Agents Actions. 1992;38:407–413
  23. Shinohara T, Sakurada C, Suzuki T, Takeuchi O, Campbell W, Ikeda S, et al. Pro-carboxypeptidase R cleaves bradykinin following activation. Int Arch Allergy Immunol. 1994;103:400–404
  24. Tan AK, Eaton DL. Activation and characterization of procarboxypeptidase B from human plasma. Biochemistry. 1995;34:5811–5856
  25. American Diabetes Association . Diagnosis and classification of diabetes mellitus. Diabetes Care. 2008;31(1):55–60
  26. Heber D, Ingles S, Ashley JM, Maxwell MH, Lyons RF, Elashoff RM. Clinical detection of sarcopenic obesity by bioelectrical impedance analysis. Am J Clin Nutr. 1996;64(3):472–477
  27. Matthews DR, Hosker JR, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412–419
  28. Friedewald WT, Levy RI, Fredrickson DS. Estimation of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499–502
  29. Schatteman KA, Goossens FJ, Scharpé SS, Neels HM, Hendriks DF. Assay of procarboxypeptidase U, a novel determinant of the fibrinolytic cascade, in human plasma. Clin Chem. 1999;45:807–813
  30. Juhan-Vague I, Renucci JF, Grimaux M, Morange PE, Gouvernet J, Gourmelin Y, et al. Thrombin-activatable fibrinolysis inhibitor antigen levels and cardiovascular risk factors. Arterioscler Thromb Vasc Biol. 2000;20(9):2156–2161
  31. Aubert H, Frere C, Aillaud MF, Morange PE, Juhan-Vague I, Alessi MC. Weak and non-independent association between plasma TAFI antigen levels and the insulin resistance syndrome. J Thromb Haemost. 2003;1(4):791–797
  32. Brouwers GJ, Leebeek FW, Tanck MW, Wouter Jukema J, Kluft C, de Maat MP. Association between thrombin-activatable fibrinolysis inhibitor (TAFI) and clinical outcome in patients with unstable angina pectoris. Thromb Haemost. 2003;90(1):92–100
  33. Silveira A, Schatteman K, Goossens F, Moor E, Scharpé S, Strömqvist M, et al. Plasma procarboxypeptidase U in men with symptomatic coronary artery disease. Thromb Haemost. 2000;84:364–368
  34. Santamaría A, Martínez-Rubio A, Borrell M, Mateo J, Ortín R, Fontcuberta J. Risk of acute coronary artery disease associated with functional thrombin activatable fibrinolysis inhibitor plasma level. Haematologica. 2004;89:880–881
  35. Montaner J, Ribó M, Monasterio J, Molina CA, Alvarez-Sabín J. Thrombin-activable fibrinolysis inhibitor levels in the acute phase of ischemic stroke. Stroke. 2003;34(4):1038–1040
  36. Kolacz E, Lewandowski K, Zawilska K. The role of thrombin activatable fibrinolysis inhibitor in disturbances of fibrinolytic system in obesity. Pol Arch Med Wewn. 2005;113(5):424–430
  37. Polac I, Stetkiewicz T, Stachowiak G, Jedrzejczyk S, Pertynski T, Pakalski A, et al. Evaluation of the effect of obesity on selected haemostatic and fibrinolytic parameters in peri- and postmenopausal women. Pol Merkuriusz Lek. 2002;13(75):182–184
  38. Song CY, Kim BC, Hong HK, Kim BK, Kim YS, Lee HS. Biphasic regulation of plasminogen activator/inhibitor by LDL in mesangial cells. Am J Physiol Renal Physiol. 2002;283(September (3)):F423–F430
  39. Allison BA, Nilsson L, Karpe F, Hamsten A, Eriksson P. Effects of native, triglyceride-enriched, and oxidatively modified LDL on plasminogen activator inhibitor-1 expression in human endothelial cells. Arterioscler Thromb Vasc Biol. 1999;19(May (5)):1354–1360
  40. Gils A, Alessi MC, Brouwers E, Peeters M, Marx P, Leurs J, et al. Development of a genotype 325-specific proCPU/TAFI ELISA. Arterioscler Thromb Vasc Biol. 2003;23(6):1122–1127

PII: S1871-403X(10)00014-1

doi: 10.1016/j.orcp.2010.05.001

Obesity Research & Clinical Practice
Volume 4, Issue 4 , Pages e271-e276 , October 2010

Article Tools